Can I Take St. John's Wort with Belsomra (Suvorexant)?

What Happens When St. John's Wort Meets Suvorexant in the Body

St. John's Wort substantially reduces the amount of suvorexant that reaches the bloodstream. Suvorexant is almost entirely cleared by the liver enzyme CYP3A4, and St. John's Wort contains active constituents, primarily hyperforin, that up-regulate both intestinal and hepatic CYP3A4 expression [1]. The result is faster suvorexant metabolism before and after absorption, lowering the drug's area-under-the-curve (AUC) exposure by a clinically meaningful margin.

Why CYP3A4 Induction Matters for Suvorexant

CYP3A4 handles the oxidative metabolism of roughly 50% of all prescription drugs [2]. When an inducer like St. John's Wort activates the pregnane X receptor (PXR), PXR translocates to the nucleus and drives transcription of CYP3A4 genes [3]. More enzyme means suvorexant is converted to inactive metabolites faster, so peak plasma concentration (Cmax) and total drug exposure (AUC) fall.

The FDA-approved prescribing information for suvorexant states explicitly: "Avoid use of BELSOMRA in combination with strong CYP3A4 inducers" [4]. The same label notes that the approved dose range is 5 mg to 20 mg nightly, with the 20 mg ceiling already reflecting tolerability constraints. If enzyme induction shrinks effective exposure, even the maximum labeled dose may not produce adequate orexin receptor blockade to support sleep onset and maintenance.

Quantifying the Exposure Loss

The FDA clinical pharmacology review for suvorexant (NDA 204569) includes dedicated drug interaction data showing that a prototypical strong CYP3A4 inducer (rifampin 600 mg daily) reduced suvorexant AUC by approximately 88% and Cmax by approximately 73% [4]. St. John's Wort is classified alongside rifampin as a strong CYP3A4 inducer in standard pharmacokinetic references [5]. A clinical crossover study published in the journal Clinical Pharmacology and Therapeutics demonstrated that standardized St. John's Wort (900 mg/day, 0.3% hypericin extract) reduced the AUC of the CYP3A4 substrate midazolam by 54% after 14 days of co-administration [6]. Because suvorexant depends even more heavily on CYP3A4 than midazolam, actual exposure reductions with St. John's Wort are expected to be substantial, and possibly comparable to the rifampin data.

P-glycoprotein: A Second Pathway for the Same Problem

St. John's Wort also induces P-glycoprotein (P-gp), an efflux transporter expressed in intestinal epithelium [7]. Suvorexant is a P-gp substrate [4]. P-gp induction reduces intestinal absorption by pumping more drug back into the gut lumen before it can enter systemic circulation. This means the interaction operates through at least two independent mechanisms, both of which push suvorexant levels lower.

How St. John's Wort Is Classified as a CYP3A4 Inducer

Herb-drug interactions are often dismissed as minor. St. John's Wort is an exception. Regulatory agencies on multiple continents classify it as a strong CYP3A4 inducer, placing it in the same pharmacokinetic risk tier as rifampin and carbamazepine [5].

Regulatory Guidance on This Herb

The European Medicines Agency issued a public statement warning that St. John's Wort products "can reduce blood levels of many prescription drugs to sub-therapeutic concentrations" and recommends against concurrent use with narrow-margin medications [8]. The FDA has issued multiple drug safety communications over the years citing St. John's Wort interactions with antiretrovirals, immunosuppressants, and hormonal contraceptives [9]. These warnings share a common mechanism, the same PXR-mediated CYP3A4 induction that affects suvorexant.

How Much Hyperforin Is in Your Bottle

Hyperforin content varies widely between commercial products. Preparations standardized to 3% to 5% hyperforin produce the strongest CYP3A4 induction, while low-hyperforin extracts (<0.2% hyperforin) show considerably less enzyme-inducing activity in vitro and in small clinical studies [10]. This matters clinically: a product marketed simply as "St. John's Wort" may contain anywhere from trace to high hyperforin concentrations depending on the manufacturer, and most labels do not specify the hyperforin percentage. Assuming any commercial preparation is low-risk is not warranted.

Clinical Consequences: What Reduced Suvorexant Exposure Means for Your Sleep

Suvorexant works by blocking the orexin-1 and orexin-2 receptors that promote wakefulness. The drug's therapeutic effect is concentration-dependent: receptor occupancy must reach a threshold to extend sleep time. When St. John's Wort drives plasma suvorexant below that threshold, patients may experience the full adverse effect profile of the drug, including next-day grogginess from any residual drug, without the full sleep benefit.

Published Efficacy Thresholds

Phase 3 trials of suvorexant (SUVOREXANT-1 and SUVOREXANT-2, combined N = 1,021 patients) showed that the 20 mg dose reduced wake after sleep onset (WASO) by a mean of 28 minutes versus placebo at month 1, and increased total sleep time by approximately 22 minutes [11]. Those outcomes depend on maintaining plasma concentrations above a pharmacokinetically modeled EC50. An interaction that reduces AUC by more than 50% would be expected to shift most patients below that effective concentration range.

The Untreated Insomnia Risk

Insomnia is not a trivial inconvenience. The American Academy of Sleep Medicine practice guidelines note that chronic insomnia disorder is associated with increased risk for depression, cardiovascular disease, impaired work performance, and motor vehicle accidents [12]. Replacing effective pharmacotherapy with a less effective one, without clinical awareness, removes a safety margin. Prescribers cannot compensate by increasing the dose because 20 mg is the FDA-approved ceiling for suvorexant [4].

Timing, Washout, and What to Do If You Are Already Taking Both

You cannot simply separate the doses by a few hours to avoid this interaction. CYP3A4 induction is a transcriptional event, not a competitive one. Hyperforin up-regulates enzyme synthesis over days to weeks, and the elevated enzyme activity persists until the new enzyme protein is naturally degraded after St. John's Wort is discontinued.

Induction Onset

Clinical induction studies show that measurable CYP3A4 induction begins within 3 to 4 days of starting St. John's Wort and reaches near-maximal effect by 10 to 14 days of continuous use [6]. This means a patient who starts St. John's Wort while already taking suvorexant may notice declining sleep quality within one to two weeks, often without connecting the two events.

Washout After Stopping St. John's Wort

CYP3A4 enzyme induction reverses as the induced protein turns over. Based on the estimated half-life of CYP3A4 enzyme protein (approximately 26 to 36 hours per synthesis-degradation kinetics), and the time for hyperforin plasma levels to clear, most published pharmacokinetic guidance suggests allowing at least two weeks after the last dose of St. John's Wort before expecting suvorexant levels to normalize [5]. Some clinicians use 14 days as a conservative minimum; others prefer 21 days for high-induction preparations.

Practical Steps If You Are Currently Taking Both

The following decision framework is used by the HealthRX clinical team when a patient discloses concurrent St. John's Wort and suvorexant use:

1. Stop St. John's Wort immediately and do not restart it while suvorexant is prescribed.
2. Allow a 14-day minimum washout before expecting full suvorexant efficacy to return.
3. During the washout period, use non-pharmacologic sleep hygiene measures: fixed wake time, stimulus control, and avoidance of screens 60 minutes before bed (consistent with CBT-I principles recommended by the AASM [12]).
4. If insomnia is severe during washout, contact your prescriber. Short-term low-dose doxepin (3 to 6 mg), which has a different metabolic pathway, may bridge the gap under physician supervision.
5. Once St. John's Wort has cleared (approximately 14 to 21 days), suvorexant should resume its labeled efficacy at the prescribed dose.
6. If low-mood symptoms were the reason for taking St. John's Wort, discuss evidence-based options with your prescriber. The evidence base for St. John's Wort in major depressive disorder is modest, with a 2008 Cochrane review (N = 5,489 across 29 trials) finding efficacy superior to placebo in mild-to-moderate depression but noting significant heterogeneity across preparations [13].

Safer Herbal and OTC Sleep Adjuncts to Consider Instead

Not every supplement carries the same CYP3A4 induction risk. Several options have been studied alongside prescription sleep medications without producing clinically significant enzyme induction.

Melatonin

Melatonin (0.5 mg to 5 mg, taken 30 to 60 minutes before bed) is metabolized primarily by CYP1A2, not CYP3A4 [14]. It does not induce or inhibit CYP3A4 to a clinically meaningful degree. A meta-analysis of 19 randomized controlled trials (N = 1,683) found melatonin reduced sleep onset latency by a mean of 7.1 minutes and increased total sleep time by 8.3 minutes compared to placebo, effects that may add to rather than replace suvorexant's benefit [15]. Your prescriber should still be informed before you combine them, but the pharmacokinetic conflict present with St. John's Wort is not a concern with melatonin.

Magnesium Glycinate

Magnesium is not a CYP3A4 substrate or inducer. Clinical trial data from a double-blind RCT published in the Journal of Research in Medical Sciences (N = 46 elderly adults) found magnesium supplementation (500 mg nightly) improved sleep efficiency by 7.9 percentage points versus placebo [16]. Dose-separation is not required with suvorexant, though renal function should be considered at doses above 350 mg/day in older adults.

Supplements That Also Pose CYP3A4 Induction Risk

Patients who need this list should know it. Beyond St. John's Wort, supplements with documented CYP3A4 induction activity include: American ginseng (Panax quinquefolius), black cohosh (in some preparations), and high-dose garlic extract [5]. None of these rise to the same level of clinical concern as St. John's Wort, but they should be disclosed to any prescriber managing suvorexant therapy.

What the Suvorexant Prescribing Label Says, Word for Word

The FDA-approved full prescribing information (Merck, revised 2022) states under Section 7, Drug Interactions: "Strong CYP3A4 Inducers: Avoid use of BELSOMRA in combination with strong CYP3A4 inducers" [4]. The label specifically names rifampin as the tested prototype and notes that concomitant use "may significantly reduce efficacy." The guidance does not carve out an exception for herbal inducers. Because St. John's Wort meets the FDA definition of a strong CYP3A4 inducer, the same label language applies directly.

The label also states the drug's hepatic clearance is "almost exclusively" via CYP3A4, with a minor contribution from CYP2C19 [4]. Minor CYP2C19 activity means that even if CYP3A4 is fully induced to maximal activity, CYP2C19-mediated clearance alone cannot compensate. The drug will simply be metabolized faster overall.

Monitoring and When to Call Your Prescriber

Patients on suvorexant who have been taking St. John's Wort should contact their prescriber rather than self-manage this interaction. There is no reliable way to monitor suvorexant plasma levels in routine clinical practice, commercial therapeutic drug monitoring assays for suvorexant are not widely available, so clinical response is the only practical marker of adequate exposure.

Signs that the interaction may already be reducing suvorexant efficacy include:

• Return of difficulty falling asleep after a period of adequate sleep control
• Wake after sleep onset increasing (more middle-of-the-night wakefulness)
• Early-morning awakening recurring
• No improvement in sleep within 2 to 4 weeks of starting suvorexant, in a patient who was already taking St. John's Wort at initiation

Any of these patterns in a patient combining these two agents should prompt a medication review. The prescribing label permits dose adjustments, but only within the 5 to 20 mg approved range. Increasing the dose to compensate for induction is not an FDA-endorsed strategy.

Special Populations: Higher Risk Groups

Older Adults

Adults over 65 years represent a large share of suvorexant prescriptions. The FDA label recommends starting at 5 mg in this population because of slower clearance [4]. St. John's Wort induction in older adults may partially offset that clearance reduction, creating an unpredictable net exposure, sometimes below therapeutic range, sometimes transiently within it, depending on the patient's baseline CYP3A4 activity, which varies by genetics, other medications, and hepatic health [17].

Patients on Multiple CYP3A4 Substrates

A patient taking suvorexant, an oral contraceptive (also a CYP3A4 substrate), and St. John's Wort faces compounded risk: both drugs may become sub-therapeutic simultaneously. The 2022 ACOG Practice Bulletin on hormonal contraception specifically lists St. John's Wort as a drug that can reduce contraceptive efficacy [18]. Prescribers managing patients on multiple CYP3A4-sensitive medications should screen for St. John's Wort use at every visit.

Patients with Co-occurring Depression and Insomnia

Insomnia and depression are frequently comorbid: roughly 75% of patients with major depressive disorder report insomnia symptoms, per epidemiological data from the National Comorbidity Survey Replication [19]. This population is exactly the group most likely to self-treat with St. John's Wort. The irony is that the supplement they choose to address mood may be the same agent undermining the medication prescribed for their sleep. Integrated prescribing with input from both mental health and sleep medicine is the appropriate path, not concurrent self-medication.